Core Viewpoint - The company plans to acquire a 19.0526% stake in Beijing Health Technology Co., Ltd. from Chengdu Deyixin Huagu Equity Investment Partnership for 67.56052 million yuan, increasing its ownership in Beijing Health from 80.9474% to 100% [1] Group 1: Acquisition Details - The acquisition will be funded through the company's own or raised funds [1] - The stake corresponds to Chengdu Deyixin's paid-in capital of 67.37 million yuan [1] - The transaction is aimed at consolidating resources and enhancing operational decision-making efficiency [1] Group 2: Company Background - Beijing Health was established in December 2020 and serves as the sales and promotion platform for the company's main products [1] - The company focuses on the circulation of high-quality pharmaceuticals in the fields of digestive and anti-infective drugs [1] - Beijing Health has achieved profitability and its future earning capacity and operational risks are reliably estimable [1] Group 3: Strategic Implications - The acquisition aligns with the company's long-term development strategy and is expected to enhance synergy with its quality subsidiaries [1] - It is seen as beneficial for optimizing resource allocation and advancing the company's development strategy [1]